Event Overview

Achieving excellence with R&D data will enable the life sciences industry to increase the speed and quality of innovation and is thus a major source of competitive advantage. Whether researchers and informaticians deal with “big data,” “deep data” or just put their data to smarter use, it is clear that the future of R&D is dependent on both smart technologies and clever researchers. The rapid progress of innovation in software and powerful hardware now allows human researchers to interpret masses of amounts of raw data in unique ways and is redefining the R&D business model. The benefits range from discovery and “omics” research, through to clinical trials and to real patients in the real-world. However, it is major technical, financial, and operational challenge to turn “messy” data into structured data, that can be used for advanced analytics that can spot opportunities and achieve true insights. Some of the most promising areas of technological innovation making rapid progress include, for example, artificial intelligence, machine learning, cloud computing and the blockchain (distributed ledgers). There is also huge potential for efficient collaborations between the life science industry, technology companies, academic researchers, health systems, physicians, and health insurers. A deeper convergence between key stakeholders and advanced technologies will facilitate the discovery and development of powerful therapies, devices and advanced diagnostics to benefit patients.

The “R&D Data Intelligence Leaders Forum” is the must attend event for those senior decision-makers, researchers and technologists, looking to make the shift towards an integrated R&D and data strategy and for those looking to improve their implementation of data-driven approaches to enhance R&D decision-making and intelligence.

Speakers List

Pharma & Biotech

Global Head Technology, Architecture, Digital Drug Development
Novartis, Switzerland

Senior Vice President and Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme, USA

Co-founder and Chairman of the Supervisory Board
CureVac, Germany

Associate Director, Information Systems
Novartis, Switzerland

Principal Scientist, Scientific Information Management
Roche Innovation Center Basel, Switzerland

Principal Scientist
Biogen, USA

Principal Scientist, Toxicology Project Leader
Roche, Switzerland

Global Head of Portfolio Management, Medical, Digital and RWE Solutions,
Novartis, Switzerland

Senior IT Project Manager Specialized in Health IT
Roche, Switzerland

Head of Discovery Informatics
e-therapeutics, UK

Head Computational Biology and Stats, Target Sciences
GSK R&D, UK

Disruptors

CSO
Numerate, USA

CTO
Insilico Medicine

CEO
Image Analysis Group, UK

Founder and CEO
Iktos, France

Co-Founder
Nebula Genomics, USA

Co-Founder & CSO
Shivom, Germany

CEO, Evonetix, UK

CTO
Intellegens, UK

Co-Founder & CEO
docdok.health

VP Pharma (EMEA)
Medisafe, UK

Co-Founder and CTO
Zebra Medical Vision, Israel

CEO
icometrix, Belgium

Head of Chemoinformatics
Exscientia, UK

Founder & CEO
aparito, UK

Co-founder and CEO,
FeetMe, France

Chief Executive Officer, Chief Scientist, TheraPanacea, France

Founder and Managing Partner
Pool Global Partners, USA

MedTech Industry

Principal Scientist - Medical Biomarker Research Oncology
Philips, Netherlands

Head of Digital Technology & Innovation, Germany
Siemens Healthineers, Germany

EMEA privacy consultant
Medtronic, Netherlands

Vice President, Innovation Program Manager
Philips Research

 

President and CEO
Dacadoo, Switzerland

Technology Companies

Sr. Program Manager, Healthcare & Life Sciences
Google Cloud, USA

CEO
DNAnexus, Inc., USA

Academic Researchers

Distinguished Professor, University of Colorado
& Co-founder, Amgen, Applied Biosystems, USA

Professor of Bioinformatics, Institute of Molecular Life Sciences (IMLS) and Swiss Institute of Bioinformatics (SIB), University of Zurich
Member of Global Alliance for Genomics and Health (GA4GH)

 

Research Fellow
Clinical Informatics Research Unit, University of Southampton

Centre Head, Quantitative Biology Center Tübingen, Germany

Professor in Bioinformatics, Director of the Biotechnological center
Technical University Dresden, Germany

Independent Thought Leaders

Chair, European Connected Health Alliance, UK

Founder & CEO, Patient In Focus
Chairwoman, EUPATI

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

Hospitals and Health Systems

Director of Innovation, Development and Therapies
Surrey and Borders Partnership NHS Foundation Trust , UK

Chief Technology & Innovation Officer
Inselspital, University Hospital Bern, Switzerland

Executive Vice President and Chief Digital Officer
Jefferson Health, USA

Professor of Machine Intelligence
University of Surrey, UK

EXPERT SOLUTION PROVIDERS

Senior Application Scientist
Chemaxon, Hungary

Research Manager
Deloitte UK Centre for Health Solutions

Event Structure

Photo Gallery

Event Program

Strategic Developments in R&D Innovation

Day 1 - 23rd January, 2019

Stream Overview

Data is redefining the R&D model and enabling better decision-making and innovation. Senior-level thought leaders from both the R&D and technology perspectives will be presenting the best technologies and approaches of today which are already creating a proven impact in R&D and which will be crucial for the research demands of tomorrow. These speakers will also discuss which technological, financial, regulatory, and operational challenges need to be overcome to ensure that key insights are achieved and that patients’ benefits are dramatically enhanced through R&D intelligence.

08.30
Registration & Coffee
08.50
Chairperson’s Opening Remarks

Executive Vice President and Chief Digital Officer
Jefferson Health, USA

KEYNOTE PRESENTATION

09.00
My Adventures in Biotechnology

Professor Marvin Caruthers has been active in biotechnology since 1980 when he, along with several other scientists and venture capitalists, was a co-founder of Amgen and Applied Biosystems.  The chemical methodologies he developed for synthesizing DNA and RNA represent one of the cornerstone technologies leading to the success of these two companies and generally the revolution in biotechnology. Since then he has been a co-founder of several additional biotechnology companies with miRagen Therapeutics being the most recent. Through the early history of these companies, he will outline the challenges and rewards of starting new biotechnology companies.

Distinguished Professor, University of Colorado
& Co-founder, Amgen, Applied Biosystems, USA

Precision Medicine

09.30
Precision medicine tools to optimize immune-oncology drug development
  • PD-1 Antibody initially studied in a known immune responsive cancer – melanoma
  • Addressable malignancies identified by a big data enabled screening phase 2 basket approach
  • Monotherapy activity by lines of therapy identified by precision medicine enabled patient selection and drug development
  • Precision medicine tools identify additional enrichment approaches along with potential resistance biology thereby informing:
  • Combination therapy development

Senior Vice President and Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme, USA

R&D INNOVATION

10.00
Blockchain: What are the Pharma use cases? What could be the new business models created by this technology combined with AI?

Blockchain is the one of the most talked about technologies .With the potential exceeding any other to revolutionize the healthcare industry, it is crucial to first understand the nature of blockchain technology, to distinguish the hype from the reality and then to see real-world case studies of how blockchain, combined with other technology such as AI, will be  applied to healthcare systems.

Global Head Technology, Architecture, Digital Drug Development
Novartis, Switzerland

10.30
Networking & Coffee

 Sponsored by:

11.00
Has AI arrived in healthcare yet?

This speech will talk about the hope, the disillusion and the reality check of Artificial Intelligence as a tool utilized in modern medicine. The focus will be on real examples as well as promising developments. Additionally, the scope will touch a variety of different specialties in health care, and won’t stop at imaging processing only, as in many current discussions.

Last but not least, the discussion will provide a business view for both, vedors and healthcare organizations alike.

Chief Technology & Innovation Officer
Inselspital, University Hospital Bern, Switzerland

11.30
Healthcare IT innovations that are connecting Patients, Providers & Payers – Connected Health

Executive Vice President and Chief Digital Officer
Jefferson Health, USA

12.00
AI for healthcare: towards precision medicine and medical decision support

Medicine is reaching a turning point: Experts believe that in just a few years, artificial intelligence will greatly help doctors make diagnostic decisions and plan treatments. In addition, patients are expected to benefit from increasingly personalized approaches and better care. This talk will present a number of examples that show how AI can make an impact at different levels along the healthcare workflow and can pave the way for precision medicine and advanced decision support.

Head of Digital Technology & Innovation, Germany
Siemens Healthineers, Germany

12.30
Health scoring and AI-based lifestyle navigation

President and CEO
Dacadoo, Switzerland

13.00
Luncheon Network
14.00
How the NHS, industry and academia are pioneering technological solutions to improve the lives of older patients

Dr Helen Rostill, Director of Innovation and Development at Surrey and Borders Partnership NHS Foundation Trust and Payam Barnaghi, Professor of Machine Intelligence at the University of Surrey will discuss the importance of cross collaboration between the NHS, industry and academia as health providers struggle to meet the needs of ageing populations.  They will cover the innovative TIHM (Technology Integrated Health Management) for dementia project that is using artificial intelligence to enable clinicians to identify and predict ill  health in people with dementia living at home as well as other innovative studies that they are involved in. They will also discuss the operational, financial, technological  and regulatory challenges of cross-collaborations in health.

Director of Innovation, Development and Therapies
Surrey and Borders Partnership NHS Foundation Trust , UK

Professor of Machine Intelligence
University of Surrey, UK

14.30
Data Empowering Patients

The presentation is based on my journey as a heart patient and athlete. How using data from my implanted device, wearable devices and performance signals allowed me to get my life back.  Next how do we scale my success to others and have a positive impact on the patient experience. How cloud computing enables these solutions. 

Sr. Program Manager, Healthcare & Life Sciences
Google Cloud, USA

CLOUD COMPUTING SOLUTIONS FOR LIFE SCIENCES

15.00
Extreme-Scale Cloud-Based Infrastructure needed for global genomic data
  • Cloud genomic data sets are approaching a total of 250 Petabytes representing an unprecedented resource for research and clinical applications
  • Extreme-scale cloud-based compute and tools are required to federate and utilize the emerging global resource, conforming to localized compliance requirements
  • A rapid evolution in data resource architecture and applicable tools is required, with an important role to be played by Artificial Intelligence

CEO
DNAnexus, Inc., USA

15.30
Networking & Coffee Sponsored by 2KMM
16.00
Measuring the return from pharmaceutical innovation 2018

The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.

Research Manager
Deloitte UK Centre for Health Solutions

16.30
Panel Discussion: Technology and the future of medicine
  • R&D Innovation – External vs. Internal and where are the future blockbuster drugs coming from?
  • What are the key attributes of the future, visionary R&D leaders?
  • Data-Driven Drug Development: Establishing strategy & data governance for an effective use of big data in the R&D process.
  • Harnessing the power of Precision Medicine and genomics through converging technologies.

Global Head Technology, Architecture, Digital Drug Development
Novartis, Switzerland

Senior Vice President and Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme, USA

Distinguished Professor, University of Colorado
& Co-founder, Amgen, Applied Biosystems, USA

Head of Digital Technology & Innovation, Germany
Siemens Healthineers, Germany

17.20
Chairperson’s Closing Remarks
17.30
End of day one

18.30 - Exclusive Networking Dinner for Event Participants

Networking Dinner - Sponsored by:

R&D IT & Bioinformatics

Day 2 - 24th January, 2019

Stream Overview

One of the key barriers to achieving success in R&D from a dedicated “big” or “deep” data strategy is how to realise R&D potential with the technical capabilities and limitations of IT. The cost of data storage, management, and analysis may be declining rapidly, allowing Big Data to become more realistic than ever, yet which is still an immense challenge. Being able to predict the IT investments into modern infrastructure, advanced software, and high-level security, which will achieve a return on investment is extremely difficult, especially given the wealth of expensive technological options. This stream will analyse the IT possibilities of today and take a peek into the near-future. The audience will also have a chance to hear examples from recent implementations of AI-powered technology within the traditional IT infrastructure. Participants will appreciate how informaticians and technologies can facilitate R&D teams to achieve unique insights into large data sets to increase the intelligence of the whole R&D organization.

08.30
Registration & Coffee
08.50
Chairperson’s Opening Remarks

Senior Application Scientist
Chemaxon, Hungary

STRATEGIC APPROACHES TO DATA MANAGEMENT

09.00
Digital Healthcare Solutions – From big data to clinical impact
  • Opportunities of leveraging big data in the context of quadruple aim healthcare
  • Basic requirements and technological solutions, opportunities offered by the cloud to bridge disciplines and care settings
  • Implementation and organizational aspects of digital solutions
  • Outcomes, demonstrated by some examples, in the field of oncology and orchestrated care. 

Vice President, Innovation Program Manager
Philips Research

 

09.40
Intelligent approaches to data curation: Experiences and perspectives.
  • Harmonizing data and metadata across different systems is key for a data-driven business. It is also an expensive and slow process.
  • To which extent can we automate or semi-automate data curation processes? It’s a multi-faceted problem.
  • Experiences and ideas in the use of rules, machine learning, and AI systems to automate the data curation process.
  • Limitations, value and perspective developments.

Associate Director, Information Systems
Novartis, Switzerland

10.20
Strategic approaches to data management: Data Governance, Federation & Interoperability in action

Principal Scientist, Scientific Information Management
Roche Innovation Center Basel, Switzerland

11.00
Networking & Coffee - Sponsored by:

DATA-DRIVEN DRUG DISCOVERY

11.30
Improving cancer chemotherapy with structure-based drug repositioning
  • Redivia Discovery Engine (RDE), an AI algorithm suite and data-warehouse for structure-based drug repositioning.
  • RDE in a use case in cancer.
  • Starting from a failed inhibitor of the cancer target Hsp27, RDE discovers a malaria drug, which acts as a potent inhibitor of Hsp27 and which provably reduces resistance to a cancer chemotherapy.
  • Redivia Discovery Engine is not limited to cancer and is applicable in other disease areas and targets.

Professor in Bioinformatics, Director of the Biotechnological center
Technical University Dresden, Germany

12.10
Building an efficient infrastructure for data-driven cancer care

Multi-layer omics (genomics, transcriptomics, proteomics and metabolomics) data stores, intuitive user interfaces and automated bioinformatics processing pipelines build the bases for integrating heterogeneous data for cancer care and research. Our data-driven process has been instrumental in a multitude of clinical oncology studies and builds the basis for Tübingen’s approach to individualizing cancer therapy via epitope-based vaccines. Through the implemented process for data and project management we were able to reach a high degree of automation on the way from tumor tissue to the presentation in the molecular tumor board.

Centre Head, Quantitative Biology Center Tübingen, Germany

12.50
Luncheon Break
13.50
Design of an AI system for drug discovery
  • AI systems have the potential of accelerating drug discovery by increasing the time scientists spend on problem solving
  • Multiple machine learning models can be used for driving multiparameter optimization
  • The use of statistical analysis of the machine learning models in an AI system can provide information about the reliability of the predictions

Principal Scientist
Biogen, USA

DATA SHARING & INTEROPERABILITY

14.30
Technologies and applications for managing and sharing data
  • General considerations on data complexity in pharmaceutical R&D
  • How to extract and consolidate knowledge from large amounts of structured and unstructured data.
  • Integration of in vivo safety data, analysis and visualization
  • Format standardization to enable study data exchange
  • Collaboration between Research and IT - how to maximize synergies to achieve a common goal

Principal Scientist, Toxicology Project Leader
Roche, Switzerland

15.10
Panel Discussion: Next-generation big data IT infrastructure
  • Developing an AI-powered technology solution for accelerated drug discovery and better drug performance prediction ability.
  • Technologies and applications for managing and sharing data.
  • Cloud-based Vs Physical infrastructure & decision-making considerations for each
  • Blockchain technology and its potential to provide the solution for connecting large amounts of information on disparate networks to a common infrastructure and to create an integrated solution for existing health IT interoperability.

Associate Director, Information Systems
Novartis, Switzerland

Principal Scientist
Biogen, USA

Centre Head, Quantitative Biology Center Tübingen, Germany

Professor in Bioinformatics, Director of the Biotechnological center
Technical University Dresden, Germany

Vice President, Innovation Program Manager
Philips Research

 

15.50
Chairperson’s Closing Remarks
16.00
End of Day TWO

16.00 -18.00 “Meet the Disruptors” Networking & Cocktail Session - Meet our panel of pioneers who are shaking up today’s R&D paradigm.

R&D Disruptors

Day 2 - 24th January, 2019
Innovative start-ups and small biotech's

Stream Overview

This unique day of discussion will bring together 20+ speakers from hand-picked, small, highly-innovative companies that have potential to disrupt how future medicines are discovered and developed. New and emerging technology such as AI, big data analytics, blockchain, digital health approaches have already found their place in R&D innovation and are very likely to have an immensely positive impact on the future of life sciences. Key areas covered in the first half of the day will include AI for drug discovery, AI applications in clinical research and imaging, the intersection of blockchain with genomics research, as well as synthetic biology.

The second part of this day will be focused on Digital Health as the convergence of connected health, m-health, quantified-self, genomics, diagnostics, social media, electronic medical records, and other exciting technologies and trends. Digital health is among the key phenomena driving transformation in the life science industry and in the quest for achieving patient and stakeholder value. This significant paradigm shift within healthcare and the rise of the connected patient is creating vast opportunities for life science innovators to achieve critical insights into patient needs.

08.00
Registration & Coffee
08.25
Chairperson’s Opening Remarks

Founder and Managing Partner
Pool Global Partners, USA

AI APPLICATIONS IN PHARMA R&D

08.30
AI-driven drug design across the discovery spectrum: Case studies
  • Breakthroughs in machine learning theory and practice, coupled with ready access to cloud-based supercomputing resources and ever-increasing amounts of experimental data, are enabling truly AI-centric processes for small molecule drug design where predictive models successfully substitute for laboratory assays throughout the critical discovery path.
  • This presentation will describe how diverse machine learning techniques, ranging from multidimensional and multitask boosting to deep neural networks, can extract accurate, scaffold-independent, ligand-based predictive models for important phenomena:  target binding, functional activity, selectivity, PK/ADME properties, and toxicity.  Applications of these models will be illustrated with examples from therapeutic programs and discussed in terms of their potential to enhance success/reduce attrition in drug discovery.

CSO
Numerate, USA

08.50
Next-Generation Artificial Intelligence for Drug Discovery

CTO
Insilico Medicine

09.10
Re-energising small molecule drug discovery

The optimisation trajectory of hit to lead to candidate is the most expensive part of drug discovery. Exscientia’s Centaur drug discovery platform brings that cost down significantly by combining the strengths of AI compound design and human strategic thinking. A high level overview of the technology is presented and results are shown from a successful collaboration that resulted in the delivery of a clinical candidate in less than a year.

Head of Chemoinformatics
Exscientia, UK

09.30
Deep learning on sparse data
  • Perform deep learning on sparse data to extract out all possible information.
  • Train on encrypted data to ensure patient confidentiality and data security.
  • Real-life examples with experimental verification in drug discovery and healthcare.

CTO
Intellegens, UK

09.50
Deep Learning generative models for ligand-based de novo drug design applied to chemical lead optimization
  • Lead optimization: one of the key cost items and bottlenecks in NCE research.
  • Limitations of current technologies and the value of deep learning generative models.
  • Specific challenges to overcome in de novo design applied to multi-parameter optimization (MPO).
  • Iktos’ approach for de novo design in MPO, illustrated with results from a real-life case study on a drug discovery project.
  • Benefits, value creation potential, and avenues for future development.

Founder and CEO
Iktos, France

10.10
Networking & Coffee - Sponsored by:
10.40
Types of Artificial Intelligence (AI) to impact clinical research
  • What AI-driven data analysis would mean for Bio-Pharmaceutical R&D.
  • How machine learning is changing our approach to the assessment of outcomes.
  • Getting AI into your R&D is simple and necessary.

CEO
Image Analysis Group, UK

SYNTHETIC BIOLOGY

11.00
A radically different approach to DNA synthesis using silicon chips

Developing a novel, highly disruptive approach to gene synthesis, the technology which underpins the rapidly growing field of synthetic biology. There are two key components of this approach:

  • Novel silicon array manufactured with semiconductor microfabrication techniques and capable of independent and exquisite control at each of many miniaturised reaction sites for the synthesis of oligoncleotides.

The selective and controlled annealing of oligonucleotides in a building process aimed at assembling DNA with very low error rates.  The advantages of our technology are therefore massive parallelism and the ability to synthesize DNA at scale and with improved fidelity.

CEO, Evonetix, UK

AI FOR MEDICAL IMAGING

11.20
Transforming patient care with the power of AI

Co-Founder and CTO
Zebra Medical Vision, Israel

11.40
Unlocking the full potential of immunotherapy with artificial intelligence
  • An integrative / evidence-driven complex system approach to disease understanding using big data analytics.
  • Artificial intelligence-driven / deep learning approaches capturing the common underlying behaviour of radiomics, pathomics, and genomics.

Processing, understanding, and reasoning on massive, high-clinical, dimensional data towards predicting clinical outcomes

Chief Executive Officer, Chief Scientist, TheraPanacea, France

12.00
From pretty pictures to meaningful results - a changing world of radiology

During this presentation I will discuss the changing world of radiology and how AI based solutions and quantification are disrupting this field. This will not only impact the way medical images are interpreted and used in clinical decision making, but will also broaden the possibilities of imaging for real world and big data studies.

CEO
icometrix, Belgium

12.20
Luncheon Break

BLOCKCHAIN IN HEALTHCARE

13.20
Combining blockchain and genomic data
  • Enabling a genomics revolution by lowering sequencing costs, increasing data protection, and facilitating data access and management.
  • Decentralized storage and computation on genomics big data.
  • Data access and consent management on the blockchain.
  • Core technologies: blockchain, containers, MapReduce, Common Workflow Language.

Co-Founder
Nebula Genomics, USA

13.40
Blockchain for translational research, precision medicine, and drug discovery

Co-Founder & CSO
Shivom, Germany

Digital Health: Case studies from hand-picked companies that are effectively disrupting healthcare

14.00
Digital health initiatives by Digital Health Society

Chair, European Connected Health Alliance, UK

14.20
docdok – Streamlining communication in clinical practices and empowering real world studies

docdok.health is a Swiss Digital Health StartUp that has developed the innovative physician-patient communication platform docdok. docdok offers a solution to key pain points at the physician-patient interface. Physicians access a single digital platform for integrated secure patient communication. docdok integrates directly with the EMR and also connects to multiple patient healthcare devices. For the physician, this allows seamless streamlining of all incoming communication and data through a single channel. Every interaction is logged for liability protection and billing purposes. docdok also enables automated dissemination of appointment reminders, patient surveys and personalized content, including tailored disease management solutions. For the patient, it means easy access to the physician and personal health information through an app as well as improved care in between visits. Using the same front-end, docdok enables research organizations (e.g. university hospitals), pharmaceutical and medtech companies to conduct studies involving patient-reported outcomes and real world data capturing.

Co-Founder & CEO
docdok.health

14.40
Networking & Coffee
15.10
Using wearables to build new markers for chronic disease management: The example of mobility disorders and FeetMe
  • Wearable technology allows real-world medical grade data generation.
  • Simplicity and robustness are key for success.
  • The road from data generation to biomarkers validation.

Co-founder and CEO,
FeetMe, France

15.30
Digital Health: shifting the focus of care to the patient experience
  • Definition
  • Relevance and acceptance
  • Quality and validation

Founder & CEO
aparito, UK

15.50
Chairperson’s Closing Remarks

16.00 -18.30 “Meet the Disruptors” Networking & Cocktail Session - Meet our panel of pioneers who are shaking up today’s R&D paradigm.

Discovery & Omics Data Excellence

Day 3 - 25th January, 2019

Stream Overview

This stream will focus on how to plan and implement data-driven approaches in the drug discovery process to unlock innovation. Huge volumes of raw data can be merged with other data sets, structured, and analysed from a myriad of perspectives, not just to achieve answers to complex research questions, but also to develop new hypotheses. Attendees will understand how a dedicated R&D data strategy for precision medicines and large “Omics” data volumes can achieve deep insights that enhance R&D decision making and innovation.

 

08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks

BIG BIOMARKER DATA

09.10
Translation of the novel prostate cancer tissue biomarker PDE4D7 for treatment stratification into a clinical diagnostics (InformMDxTM)
  • Prostate cancer is the largest male tumor disease and is very heterogeneous in its biology which is reflected by very different patient-outcomes.
  • While a large group of men with prostate cancer have excellent survival prognosis, a significant cohort of patients still have very poor outcomes and need aggressive therapies.
  • Treatment of prostate cancer is associated with potential side effects which are quite significant and at serious costs.
  • Accurate risk stratification to treat those with maximum benefit is key in prostate cancer care.
  • PDE4D7 is a novel tissue biomarker which supports the treatment stratification of prostate cancer patients and is currently being translated into the clinic as a diagnostic.
  • Novel treatment strategies for prostate cancer could be developed based on the findings concerning PDE4D7.

Principal Scientist - Medical Biomarker Research Oncology
Philips, Netherlands

INNOVATIVE DRUG DISCOVERY

09.50
Mining large omics data sets for drug discovery
  • Examples of relevant genetics and genomics data in drug discovery
  • Challenges in the integration and use of omics data sets
  • Uncovering new biological insights using machine learning on omics data sets

Head Computational Biology and Stats, Target Sciences
GSK R&D, UK

10.30
Networking & Coffee
11.00
Network-Driven Drug Discovery
  • Conceptual foundations of a practical, computational approach to early drug discovery based on network biology
  • Details of the network-driven approach based on the integration of multiple data sources combined with network analytics
  • Successful validation via a number of internal of discovery projects across a range of indications and biological mechanisms

Head of Discovery Informatics
e-therapeutics, UK

OMICS AND PRECISION MEDICINE

11.40
Biological Activity of Thiomorpholino Oligonucleotides and an RNA Analogue Useful for CRISPER/CAS Research
  • New DNA analogues having amino functionality at both nonlinking internucleotide phosphorus bonds have been synthesized. These imidoamidate derivatives form duplexes with complementary DNA, are positively charged, can be transfected in the absence of lipid and are RNase H1 active.
  • Thiomorpholino DNAs (TMO) and their DNA chimeras (TMO/DNA) are new oligonucleotide analogues containing morpholino- and 2’-deoxyribonucleosides joined through thiophosphor/phosphor internucleotide linkages. The TMO and TMO/DNA chimeras were observed to have higher melting temperatures when compared to natural DNA/DNA and DNA/RNA duplexes and are active with RNase H1. These analogues are efficiently taken up by cells in the absence of lipid and stimulate biological activity in a HeLa cell dual luciferase assay. Recently thiomorpholino oligo-nucleotides have been found to be far more active than any other tested analogue in exon skipping assays involving a mouse model for Duschenne Muscular Dystrophy.

Distinguished Professor, University of Colorado
& Co-founder, Amgen, Applied Biosystems, USA

12.20
Printing Information on Drugs - 3D printing of mRNA drugs

mRNA therapeutics are more in the spotlight today than ever before.  Up to 20 clinical trials in various indications are ongoing by various companies in the fields of vaccines, enzyme replacement therapies, and oncology.  mRNAs can be applied in vivo, comprising several different proteins as cocktails, all expressed in the same tissue.  Currently undruggable targets, such as membrane receptors and intracellular proteins, can be expressed, offering a whole new horizon for treatment options.  Furthermore, each patient can be analyzed and treated individually by an mRNA vaccine or therapeutic just printed at the doctor’s office.  A vision or near-term reality?

Co-founder and Chairman of the Supervisory Board
CureVac, Germany

13.00
Luncheon Break
14.00
Connecting the silos: Genomic data standards, resources and the Global Alliance for Genomics and Health

Professor of Bioinformatics, Institute of Molecular Life Sciences (IMLS) and Swiss Institute of Bioinformatics (SIB), University of Zurich
Member of Global Alliance for Genomics and Health (GA4GH)

 

14.40
Panel Discussion: Impact of High-Performance Computing on drug discovery and translational science
  • Utilizing Big Data, focusing specifically on two phases of research: discovery, translational.
  • Next-Generation Sequencing, Proteomic & Genomic Big Data as a source of developing new Biomarkers & Personalized Medicines. How do we deal with the data bottleneck?

Professor of Bioinformatics, Institute of Molecular Life Sciences (IMLS) and Swiss Institute of Bioinformatics (SIB), University of Zurich
Member of Global Alliance for Genomics and Health (GA4GH)

 

Head Computational Biology and Stats, Target Sciences
GSK R&D, UK

15.20
Chairperson’s Closing Remarks
15.30
End of day three

Clinical & Patient-Level Data Excellence

Day 3 - 25th January, 2019
Excellence:

Stream Overview

This stream will feature best practice case studies of designing, collecting, and managing large sets of clinical-stage and patient-level data from both clinical and informatics experts. Specific attention will be paid to taking advantage of innovative real-world data generation tools, as well as the potential of new technologies such as blockchain. Key speakers will also present examples of disruptive technologies to develop secure, patient-level data, and build strategic partnerships between key industry players, academia, and patient networks to achieve patient-centric health outcomes.

08.30
Registration & Coffee
09.00
Chairperson’s Opening Remarks

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

RWD ANALYTICS

09.10
Engaging with a growing Health Data Ecosystem

Global Head of Portfolio Management, Medical, Digital and RWE Solutions,
Novartis, Switzerland

BLOCKCHAIN FOR RWD

09.40
Blockchain to support Precision Medicine and empower patients

Presentation on the feasibility and benefits of creating a vendor/pharma independent, open source, Blockchain network to keep the real identity of the patients protected while allowing the possibility to:

  • Link different anonymized datasets for more powerful advanced analytics;
  • Link real world data with clinical trial data and diagnostics data;
  • Seek additional patient consent;
  • Inform patients on the outcome of the research they participated in and inform them on how their data is supporting novel medical research;
  • Seek additional information from patients on treatment outcome;
  • Empower the patients to choose which of their data can be used for what medical research;

Senior IT Project Manager Specialized in Health IT
Roche, Switzerland

AI AND NATURAL LANGUAGE PROCESSING

10.10
Making sense from unstructured data: Using NLP and machine learning to make sense of posts that patients generate on social media

VP Pharma (EMEA)
Medisafe, UK

10.40
Networking & Coffee

DATA EMPOWERING PATIENTS

11.10
Empowered patient perspective

Founder & CEO, Patient In Focus
Chairwoman, EUPATI

11.40
Data fueling patients' power?

Do patients really care about their healthcare data?
Some great patients initiatives in France: 
- Renaloo "Moi patient" platform initiative
- Seintinelles: patients sharing data for research on cancer
 Conclusions: difficulties for patients to access data ; patient's new generations

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

DATA PRIVACY AND PROTECTION

12.10
What is the impact of the General Data Protection Regulation?
  • GDPR: seven months down the road
  • Has GDPR stopped or stimulated the R&D?
  • What are the R&D privacy risks you need to know about?
  • How to ensure that you can effectively continue to use your R&D data?

EMEA privacy consultant
Medtronic, Netherlands

12.40
Luncheon Break

PRE-COMPETITIVE RESEARCH COLLABORATIONS

13.40
Pre-competitive sharing of data to maximise research collaborations

Research Fellow
Clinical Informatics Research Unit, University of Southampton

14.10
Improving outcomes for people with dementia and their carers using artificial intelligence

Dr Helen Rostill, Director of Innovation and Development and Payam Barnaghi Professor of Machine Intelligence at University of Surrey, will discuss the TIHM (Technology Integrated Health Management) for dementia study, the first programme of work – in the UK or internationally – that has developed and installed an Internet of Things based intervention to support management of dementia in the community. They will cover the pioneering work in developing machine learning algorithms to support early intervention and reduce people’s need for hospital admission. One of the algorithms designed can detect the symptoms of a urinary tract infection, a top five cause of unplanned hospital admission among older people in the UK.

Director of Innovation, Development and Therapies
Surrey and Borders Partnership NHS Foundation Trust , UK

Professor of Machine Intelligence
University of Surrey, UK

14.40
Panel Discussion: Technology and strategic approaches enabling the use of consumer & patient data in R&D
  • Real-world big data & unlocking the power of real-world data assets.
  • Good data governance practices: Instituting policies on ethics, privacy, transparency and legal issues.
  • Blockchain and it’s possible use for personal health record storage.

Global Head of Portfolio Management, Medical, Digital and RWE Solutions,
Novartis, Switzerland

Senior IT Project Manager Specialized in Health IT
Roche, Switzerland

VP Pharma (EMEA)
Medisafe, UK

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

Director of Innovation, Development and Therapies
Surrey and Borders Partnership NHS Foundation Trust , UK

Professor of Machine Intelligence
University of Surrey, UK

15.20
Chairperson’s Closing Remarks
15.30
End of day three

Senior R&D executives: Scientific Officers, Chief Information Officers, Chief Technology Officers, Knowledge & Data Management (Discovery, Clinical & Real-World Data), R&D Analytics, Informatics, R&D Innovation, External Alliances & Innovation, R&D Strategy.

Drug Discovery: Drug Discovery, R&D, Lead Identification & Target Validation, Screening, Translational R&D, Genomics & Proteomics, Biomarker R&D, Senior Scientist, Biostatistics, Biometric, Precision Medicine, Personalised Medicine, Computational Biology.

R&D and IT Infrastructure: Information Technology & Services, R&D IT, IT Hardware & Infrastructure, Software, Database Management, Vendor management

Data Management: Clinical Development, Clinical Data Management, e-Clinical, Electronic Data Management, Health Economics & Outcomes Research, Real-World Evidence Generation, Late-Phase Research, Epidemiology, Drug safety & Pharmacovigilance, Medical Information.

Digital & Connected Health: eHealth, mHealth, Connected Health, Digital Health Solutions, Strategic Medical Innovation, Business Development, Strategic Collaborations, Alliances, External Innovation, Patient Engagement

Platinum Event Partner

Event Partners

Media Partners

Related Podcast

Speaker Biographies

Pascal Bouquet

Global Head Technology, Architecture, Digital Drug Development
Novartis, Switzerland

Senior Technologist and Enterprise Digital Architect, Pascal has more than 20 years of experience leading global IT organizations, building high performing teams, managing Enterprise Architecture teams, leading digital innovation and delivering complex large scale, global programs. He joined Novartis and the Pharma industry in 2013 and is in charge of the technology evolution of the Drug Development Information System. Passionate by the  new technology and by the transformation of the healthcare industry, excited to deploy a mix of Digital, IT technology, semiconductor and pharmaceutical knowledge to drive the acceleration in eHealth and digital medicine, Pascal advocates for a Blockchain consortium to accelerate the adoption of this technology in the healthcare in the industry

Roy D. Baynes

Senior Vice President and Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme, USA

Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Sharp & Dohme (MSD). He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.

Ingmar Hoerr

Co-founder and Chairman of the Supervisory Board
CureVac, Germany

CEO and co-founder of the biopharmaceutical company CureVac AG, incorporated in 2000, is Dr. Ingmar Hoerr. His entrepreneurship was motivated by a surprising discovery during his doctoral research at the University of Tuebingen. Experiments conducted for his research showed that the mRNA molecule class can be injected into tissue directly and is capable of expressing genes into proteins effectively as well as generating a strong specific immune response, contrary to what had previously been believed. From this key discovery, the founders built up a company that was the first ever to treat a human subject with an mRNA drug and that is now a leading German “unicorn” in the research and development of mRNA-based drugs.

Ingmar Hoerr received his PhD from the University of Tübingen and his MBA from Danube University, Krems, Austria. He currently advises the European Commission as member of the High Level Group of Innovators in developing a European Innovation Council and is juror of the founder prize Weconomy.

Andrea Splendiani

Associate Director, Information Systems
Novartis, Switzerland

 

Andrea Splendiani (M), PhD is Associate Director in NIBR Informatics. He has more than 15 years of experience in data integration, ontologies, and semantic web technologies. A computer scientist by background, he has been working in a variety of roles and life sciences environments, including functional genomics, systems biology and knowledge engineering. His professional activities and research focus on the interface between knowledge organization and its downstream exploitation. Since 2014 he is in Novartis, where he is responsible for the development of advanced data curation approaches

Martin Romacker

Principal Scientist, Scientific Information Management
Roche Innovation Center Basel, Switzerland

Martin is a Data and Information Architect in Technical Solution Delivery and Architecture in Pharma Research and Early Development Informatics at F. Hoffmann-LaRoche. His main areas of activities are terminology management, semantic engineering, scientific data curation, text mining and semantic search. Martin has been active in the development and deployment of Data Standards within the organization but also teaming up with external partners. During his work Martin puts a particular emphasis on cross-functional data organization and the definition for Data Quality KPIs. As a part of pREDi's precompetitive engagements Martin has been contributing to projects of the Pistoia Alliance and the Innovative Medicine Initiative.
Before joining Roche Martin worked at the Novartis Institutes of Biomedical Research as a Senior Knowledge Engineering Consultant leading various ontology development and text mining projects such as the implementation of a set of BioAssay Ontologies. Martin was also the Managing Director of a Start-Up company in Freiburg (Germany) where he focused on R&D activities for NLP. He holds a PhD in Computation Linguistics from the University of Freiburg on Semantic Interpretation of technical and medical texts.

Istvan Enyedy

Principal Scientist
Biogen, USA

In the past 20 years Istvan J Enyedy has been involved in new target
evaluation, hit finding, and hit-to-lead optimization projects for several types of target classes using both ligand and structure-based methods. He is coauthor on more than 40 publications and 12 patents/applications. He received his PhD in 1998 at Catholic University of America, Washington DC, and did postdoctoral training in Dr. Shaomeng Wang’s group at Georgetown University Medical Center, Washington DC. Between 2001 and 2008 he worked at Bayer Pharmaceuticals, West Haven CT and Novartis Institutes for Biomedical Research in Cambridge MA. Since August 2008 he has been working at Biogen Idec, in Cambridge MA.

Alessandro Brigo

Principal Scientist, Toxicology Project Leader
Roche, Switzerland

Alessandro Brigo is a Principal Scientist and Toxicology Project Leader in the Pharmaceutical Sciences organization at the Roche Innovation Center Basel, Switzerland. In this role Alessandro leads drug discovery and development programs from a toxicology perspective to provide expert support through all development phases and for marketed products.
In addition, Alessandro has been working in the field of Computational Toxicology since 2006, with great emphasis on the assessment of potential genotoxic impurities in active pharmaceutical ingredients at development and marketing stages. On the topic, Alessandro authored and co-authored 6 peer-reviewed articles and 3 book chapters.
Being highly interested in storage, accessibility and interpretation of large and complex datasets, between 2010 and 2016, Alessandro has been serving as global business lead of the Roche Safety Data Integration (SDI) initiative and the SEND-readiness program, both of which aim at delivering Standards for Integration and Exchange of Nonclinical Data.
Alessandro is a pharmacist by training with a PhD in Pharmaceutical Sciences obtained at the University of Padua, Italy, and a board-certified toxicologist (DABT).

Peter Speyer

Global Head of Portfolio Management, Medical, Digital and RWE Solutions,
Novartis, Switzerland

Peter Speyer is Global Head of Real World Evidence Solutions at Novartis, responsible for managing and expanding Novartis’ Real World Evidence data and technology infrastructure, as well as creating visualizations and apps to make the data useful across the organization. Prior to his role at Novartis, Peter was Chief Data & Technology Officer at the Institute for Health  Metrics and Evaluation (IHME) at the University of Washington in Seattle. In that role, he was responsible for obtaining and managing the data that fuel IHME’s research in global and public health, and for providing powerful computational infrastructure that enables cutting edge analytics. To make IHME’s data and research results useful for others, he directed the development of the Global Health Data Exchange (GHDx) and IHME’s innovative interactive data visualizations.

Prior to joining IHME, Peter spent most of his career in strategy and product management positions in the media industry. He worked most recently in a number of leadership positions at image licensing company Corbis, including Director of Market Strategy and Director of Product Management. Before Corbis, Peter held positions in Corporate Strategy and the TV subsidiary RTL Television at German media giant Bertelsmann.

Peter holds an MBA from Temple University in Philadelphia, USA, and a Master in Business and Engineering from the Karlsruhe Institute of Technology, Germany.

Benoit Marchal

Senior IT Project Manager Specialized in Health IT
Roche, Switzerland

Benoît has an IT Master Degree from the University of Technology of Compiegne (France) and has more than 25 years’ experience leading various digitalization projects to improve and streamline the clinical research process. Before joining Roche, Benoît created and managed the startup NovaXon that provided solutions to pharmaceutical companies and hospitals to collect clinical data. Previously he worked for Medtronic in a special innovation department to explore new therapies with active medical devices. Most recently, he took the position of Roche representative in the industry collaboration EHR4CR and became a strong advocate both internally and externally of the potential of hospital real world data to support medical research. In parallel Benoît, is leading several innovation proposals to address some of the common challenges observed in precision medicine.

Jonny Wray

Head of Discovery Informatics
e-therapeutics, UK

Jonny Wray is a computational biologist with a unique background in complex systems analysis, computational biology, drug discovery informatics, and software engineering. Jonny was a Fellow in Theoretical Neuroscience at The Neurosciences Institute (New York and San Diego) where his research was aimed at understanding how brain function arises from network structure. More recently, Jonny was Director of Bioinformatics at Five Prime Therapeutics (San Francisco) where he was responsible for the informatics portion of Five Prime’s discovery platform. Jonny is currently the Head of Discovery Informatics at e-Therapeutics plc where he has been responsible for the conceptual development of their network driven discovery approach, and the design of the software platform embodying that approach.

Philippe Sanseau

Head Computational Biology and Stats, Target Sciences
GSK R&D, UK

Philippe is currently the Head of the Computational Biology and Stats Department at GSK (GlaxoSmithKline) and a GSK Senior Fellow. He is also the GSK lead for Open Targets an innovative pre-competitive collaboration located on the Genome Campus in Hinxton (UK) between the WTSI (Wellcome Trust Sanger Institute), the EBI (European Bioinformatics Institute), Biogen, Takeda, Celgene and GSK. He is also a member of the Scientific Advisory Board for the GSK and EMBL-Heidelberg strategic partnership. He serves on several academic advisory boards and funding panels in the UK and Europe. He has published more than 50 peer-reviewed papers in bioinformatics, genomics and genetics. Philippe has a PhD from the University of Rennes in France. His post-doctoral training was at the Imperial Cancer Research Fund in London (now Cancer Research UK) with a focus on Immunogenetics before joining GSK.

John Griffin

CSO
Numerate, USA

John Griffin is Chief Scientific Officer at Numerate, which has developed and applies an AI-driven approach to small molecule drug design.  He was formerly Co-Founder and Chief Scientific Officer of Theravance and Assistant Professor of Chemistry at Stanford.  John is the author of 39 publications, an inventor of 27 issued patents, and the recipient of awards including a Cope Scholar Award from the ACS and a Dean's Award for Teaching from Stanford University.  John received a B.S. in Chemistry from Hope College, a Ph.D. in Chemistry from Caltech and was a Postdoctoral Fellow at Harvard Medical School.

Alex Zhebrak

CTO
Insilico Medicine

Background in mathematics and computer science with extensive experience implementing highly scalable infrastructure and system architecture for web-based projects. Currently, he is leading R&D team of Insilico Medicine applying deep learning techniques to drug discovery, biomarker development and aging research with interdisciplinary applications of blockchain solutions to healthcare. Co-authored several educational projects in academia and MOOCs.

Olga Kubassova

CEO
Image Analysis Group, UK

Mathematician with expertise in actively managing innovation in life science companies, asset positioning, strategy, and bio-pharma investment. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.  Olga is an active researcher, co-author of 60+ publications, books, and book chapters. She is a scientific adviser to the UK government and EU funding bodies. She is a founding member of 'The 2% club' to support women in leadership positions, fellow of the Royal Society of Medicine, Royal Society of Engineering, alumni of several business leadership programs by Goldman Sachs, Oxford Said Business School, Business School of University of Leeds, alumni of Business Programme by the New York Economic Development (New York Venture Fellows), 4-time winner of the national and international 'Entrepreneur of the Year' award. 

Yann Gaston-Mathe

Founder and CEO
Iktos, France

Yann is a seasoned Pharma R&D professional, strategy consultant and biotech entrepreneur with 20+ years of experience in pharma (Servier, Ipsen), molecular diagnostics (IntegraGen) and strategy consulting (Capgemini Consulting, BearingPoint, Cepton). Yann is also a skilled data scientist with several patents and publications in the field of biostatistics and biomarkers discovery and validation.

Since 2016, Yann is the co-founder and CEO of of Iktos, a Paris based start-up company and one of the leading players in the emerging field of AI for chemical research. Iktos is focused on the development of innovative IA solutions (services and software) for de novo drug design (both ligand-based and structure-based), leveraging the recent developments of deep learning technology and more specifically DL generative models. 

Yann holds a MS Degree from Ecole Polytechnique Paris and a MS Degree in genetics from AgroParisTech.

Dennis Grishin

Co-Founder
Nebula Genomics, USA

Dennis is the Co-founder of Nebula Genomics. He holds the Boehringer Ingelheim PhD Fellow in Genetics and Genomics at Harvard University.  He is also a member of German National Academic Foundation Fellowship and holds Master's in Computer Science from Harvard University.

Axel Schumacher

Co-Founder & CSO
Shivom, Germany

Axel has over 20 years of R&D leadership experience in genomics, epigenetics, biomarker discovery, Bio-IT, and aging & longevity. He is the Author of the ‘Blockchain & Healthcare Strategy Guide’, the standard compendium for the healthcare industry. Axel translates scientific discoveries into practical applications to help understand, diagnose, and treat complex disorders, but also to promote cutting-edge technologies that could transform precision medicine and the way we age. Axel is a Faculty-Member of the Blockchain Research Institute in Toronto and holds a PhD in Human Genetics from the University of Cologne.

Tim Brears

CEO, Evonetix, UK

Tim Brears was appointed Chief Executive Officer of Evonetix in May 2017.  He previously served as Chief Executive of a number of bioscience companies, including Xention, a biopharmaceutical company specialising in the discovery and development of ion-channel-modulating drugs for the control of atrial fibrillation, and Gendaq, a company focused on the development of zinc finger proteins for gene regulation.

Prior to that, he spent ten years in the US, initially as a long-term fellow of the European Molecular Biology Organisation at Rockefeller University, New York, and subsequently as Director of Licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina.

Tim holds a PhD in molecular biology from Cambridge University and an MBA from Duke University’s Fuqua School of Business and is a Registered US Patent Agent.

Gareth Conduit

CTO
Intellegens, UK

Gareth Conduit has a track record of applying artificial intelligence to solve real-world problems. The approach, originally developed for materials design, is now being applied to design of small molecule pharmaceuticals. The method is being commercialized by startup Intellegens in collaboration with Optibrium. Gareth also maintains an academic position at the University of Cambridge.

Ulrich Muehlner

Co-Founder & CEO
docdok.health

Ulrich Muehlner is a senior healthcare executive with 18 years of industry experience. In 2016, he started GrowthCube Partners and became an active startup investor and entrepreneur to enable life-changing healthcare innovations by joining forces with scientists, innovators, and entrepreneurs, and - together - translating groundbreaking ideas, discoveries, and inventions into services and products that make a real difference to people’s lives. Dr Muehlner is particularly passionate about transforming the pharma & medtech industry and providers towards value-based healthcare through Real World Evidence, Artificial Intelligence, and Deep Learning. To fulfill this mission, Ulrich Muehlner co-founded docdok.health and developed docdok, a GDPR and HIPAA compliant cloud based solution connecting healthcare providers with their patients in the clinical and study ecosystems, 24/7, on all devices enabling to capture objective real world data (RWD) in addition to subjective patient reported outcomes (PROs) while significantly benefiting both patients and doctors. He also serves globally as board member and advisor to biopharma and digital health/health tech companies (e.g., E-Medicus, Insilico Medicine, Medicinisto), as well as international organizations and leading academic institutions. Previously, Dr Muehlner worked at Novartis and Boston Consulting Group (BCG). At Novartis he served as Director and Head Global Corporate Strategy, Global Head Outcomes Technologies Incubator. In these roles, he was responsible for the multi-billion dollar portfolio transformation strategy and spearheaded globally the digital health activities across Novartis leading to major digital health partnerships (Google/Verily, IBM, Proteus) with the aim to increase the value of the Novartis portfolio through ‘beyond-the-drug’ real-world outcomes solutions. In total, Dr Muehlner successfully executed deals with a volume of $350mn. Ulrich Muehlner studied Biochemistry in Hannover and Munich, and earned a PhD degree in Biochemistry and Molecular Biology based on his research on molecular mechanisms of cancer development at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.

Aji Barot

VP Pharma (EMEA)
Medisafe, UK

Aji is a biochemical engineer and health economist who has spent the past 16 years in various healthcare focused roles. From studying the development of gene therapies to global market access and now at the cutting edge of healthcare technology.

As the business development director at HealthUnlocked he works with academic and industry partners around the world in the design, deployment and measurement of digital health interventions.

Eyal Toledano

Co-Founder and CTO
Zebra Medical Vision, Israel

Eyal Toledano is co-founder and CTO of Zebra Medical Vision; Eyal focuses on innovation in medical imaging machine vision. Graduated with Master of Science from the MIT Media Lab. Eyal served for more than 8 years as the CTO and Advanced Technology GM for Samsung Israel R&D (STRI/Yakum). Eyal was responsible to envision, establish and manage new technological domains such as computer vision, augmented reality, and the Medical Imaging lab in Samsung Israel R&D. Before co-founding the Israeli R&D of Samsung Eyal was leading the development of challenging projects at Sun Microsystems. Eyal Toledano completed 7 years of military service in the IDF Elite Intelligence Technologies unit as officer and team leader. Eyal still hacks code every day, father to 5-year-old Yuval enjoys scuba diving, tennis and jazz.

Wim Van Hecke

CEO
icometrix, Belgium

Wim Van Hecke, PhD, is the founder CEO of icometrix. icometrix the world leader in software solutions to obtain clinically meaningful data from brain imaging scans. The fully automated icobrain software is FDA approved and has market approval in Europe, Canada, South America and Australia. The icobrain software is used in 100+ hospitals and icometrix works with the largest pharmaceutical and health tech companies for real-world and big data studies.

Wim is an academic engineer by training with two Masters degrees in applied biomedical engineering and neuroimaging, and a PhD in diffusion MRI analysis. He is author or co-author of over 150 scientific publications, has won numerous scientific awards and is frequently invited to present his work at courses, conferences and hospitals around the world.

Willem van Hoorn

Head of Chemoinformatics
Exscientia, UK

Willem van Hoorn gained a PhD in computational chemistry in the group of David Reinhoudt at the University of Twente, the Netherlands followed by a postdoc at Yale with Bill Jorgensen. He subsequently spent a decade at Pfizer Sandwich focusing on computational techniques for HTS triage and combinatorial library design. This was followed by a position as IT consultant at Accelrys (now Biovia) assisting a range of clients from small biotech to big pharma. Since 2013 he is pursuing his long term interest of applying computer algorithms to drug discovery at Exscientia.

Elin Haf Davies

Founder & CEO
aparito, UK

Elin Haf initially qualified as a Children’s nurse at Great Ormond St Children’s Hospital (GOSH), going on to gain a BSc (Neuroscience) and MSc (Research Methods). After years of recruiting children to clinical trials Elin embarked on a PhD at the Institute of Child Health (UCL) to develop a clinical outcome measure and biomarker of ataxia in children with neuro-metabolic disease.

Elin Haf was part of the paediatric team at the European Medicine Agency from 2007-2013, responsible for implementing the Paediatric Regulation in Europe. She has a personal interest in empowering children to become involved in the health / research agenda.

In January 2015 Elin Haf launched her own company, Aparito. Using wearable technology and mobile phone apps to monitor disease progression and patient well-being in real-time. The company now has studies running in the UK, India, America, South Africa, with offices in London, Berlin and Wrexham. 

When not working Elin is an adventure-addict! She played rugby for Wales A for seven years before embarking on a completely new challenge - spending 77 days rowing across the Atlantic Ocean with fellow GOSH nurse and raising £190,000 for metabolic research. In 2009 she was part of the first ever-female crew to row across the Indian Ocean, a 3,600m trip that took 78 days. Elin Haf completed a hat-trick of oceans by sailing 6,000 miles across the north Pacific. Her adventures over the years have raised £300,000 for charities close to her heart. Her book, On Tempestuous Seas holds the record for the most number of books sold in one night at the National Geographic Store in London.

Elin was appointed Team Wales Ambassador for the 2018 Commonwealth Games in Australia

More details at www.elinhafdavies.co.uk or @elinhafdavies
And www.aparito.com and @aparitohealth

Alexis Mathieu

Co-founder and CEO,
FeetMe, France

Following his studies at Ecole Polytechnique, Alexis Mathieu started FeetMe facing strong unmet clinical needs within rehabilitation. Starting form sensors design up to market access, Alexis has lead the different stages of the company within strong regulatory constraints. 

 

Alexis has built a team of 15 engineers, with broad expertise, ranging from physics to signal processing and biomechanics. He has set up a strong tech culture, including a focus on testing. For example, team members get to “dog food” the product they are building and jog around wearing the insoles, which is a testimony of their dedication! In addition, the team works day to day with physicians and key opinion leaders. 

In a matter of months, Alexis has learned to speak a clinician’s language and has built the solid relationships that are crucial to successful medtech innovation.

Nikos Paragios

Chief Executive Officer, Chief Scientist, TheraPanacea, France

Nikos Paragios (45), CEO and CSO of TheraPanacea, is also a distinguished professor of Mathematics and computer science, former director of the Center for Visual Computing at CentraleSupelec (Université Paris Saclay) and the Galen research team at Inria. Nikos has held numerous academic and industrial appointments in USA (visiting professor for Yale and Rutgers University and as an R&D manager for Siemens USA), received many prestigious international prizes for his work on the application of Imaging technology and AI to medical sciences (including the very selective MIT Under 35 global awards (2007) and the ERC grant from Europe (2011), granted to less than 1% of European researchers.

 

Sally Daub

Founder and Managing Partner
Pool Global Partners, USA

Sally Daub is a technology entrepreneur, investor and CEO. An experienced executive, Sally’s industry-wide expertise includes semiconductors, consumer electronics, AI applications in healthcare, quantum computing and blockchain, making her an in-demand advisor and board member to both private and public companies in Silicon Valley and Toronto.

As Founder and Managing Partner of Pool Global Partners, Sally is investing in the next generation deep technology innovation. Pool Global Partners combines Sally’s extensive experience in founding, funding and scaling technology companies with a global network of partners and operators. With an emphasis on operational expertise and concept-to-commercialization strategy, Sally has guided numerous technology companies through successful investor exits and IPOs.

A frequent lecturer and guest speaker at universities and events around the world, Sally is also a Fellow at Creative Destruction Lab, a leading deep technology innovation pipeline and accelerator program, where she provides mentorship to promising entrepreneurs.

Sally has been recognized with numerous awards, including Women’s Executive Network’s Top 100 Most Powerful Women (2010, 2011, 2012, 2013) and inducted into WXN’s Hall of Fame (2014).

Ralf Hoffmann

Principal Scientist - Medical Biomarker Research Oncology
Philips, Netherlands

Ralf Hoffmann is a Principal at Philips Research in Eindhoven, The Netherlands. He holds a PhD in Protein Biochemistry and Molecular Biology and an MSc in Biology from the University of Constance, Germany. After his time as a Postdoc at the University of Constance and at the University Hospital in Ulm, Germany, he moved to Sandoz Pharma, Basel, Switzerland to analyse the function and regulation of phosphodiesterases in inflammatory processes associated with asthma. After the merger between Sandoz Pharma and Ciba Geigy, he was working on target discovery for therapeutic applications in the field of Neuroscience. In 1998, Ralf left Novartis to build and lead a team performing high-throughput discovery of therapeutic targets for neurological diseases at Biofrontera Pharmaceuticals, Leverkusen, a German biotech start-up. He became a Director of Technology development and took over responsibility to develop a high-throughput expression data analysis platform to automatically analyse large-scale qPCR data for quality aspects and disease relevant gene expression signatures. In 2003, he joined Philips Research in Germany, as a Principal Scientist responsible for the development of opportunities in the area of Molecular Diagnostics and Molecular Imaging. In 2004, he moved to Philips Research in Eindhoven to establish a project aiming at the identification of novel biomarkers for the diagnosis and prognosis of cancer diseases, in particular prostate cancer. As a PI of the prostate cancer biomarker activity at Philips, he was responsible for a number of external clinical and academic prostate cancer related collaborations on the European level. He was appointed honorary Senior Lecturer (Associated Professor) at Glasgow University in 2009 due to his substantial role in supervision of several Philips-BBSRC funded PhD students.

Tobias Heimann

Head of Digital Technology & Innovation, Germany
Siemens Healthineers, Germany

Tobias Heimann is heading the German team of Siemens Healthineers global Digital Technology & Innovation department. Focus of the team is research of new algorithms and applications in the field of image analytics and AI. With 15 years of experience in the field in academia and industry, Tobias Heimann has worked on a large range of topics spanning statistical methods, machine learning, and computational modelling, and has co-authored more than 80 scientific publications.
Before joining Siemens, he received his PhD at the German Cancer Research Center in Heidelberg and worked as postdoctoral researcher at INRIA Sophia-Antipolis in France.

Hans Martens

EMEA privacy consultant
Medtronic, Netherlands

Hans Martens is currently EMEA privacy consultant at Medtronic. Formerly, Regional Privacy Manager for Europa at GSK. Hans graduated from the Nijmegen University (Biochemistry) in The Netherlands. In 1994 he became employed by Eli Lilly and Company and held a variety of positions in Sales, R&D, IT, Auditing and Privacy till 2014. This included Privacy and Data Protection Manager in Europe and registered Dutch Data Protection Officer. In 2007 Hans has completed a Master on IT-auditing and obtained his CISA certification. Furthermore, Hans obtained CPGP, CIPT, CIPP/E and CIPM certification. Hans is a trained and certified fire fighter.

Hans Hofstraat

Vice President, Innovation Program Manager
Philips Research

 

Hans Hofstraat is Innovation Program Manager at Philips Research, a position he has held since 2009. As Innovation Program Manager, Hans works with teams within Philips Research, and with colleagues in Business and Markets, on innovations in the area of Oncology, Neurology, and Universal Access to Care, combining deep clinical insights with the opportunities offered by digital healthcare. Together with partners within and beyond Philips, Hans is passionate about identifying major needs in the health-technology domain, and to address these by developing meaningful solutions underpinned by proven outcomes. His aim is always to achieve innovations that broaden access to appropriate care and improve quality of life for patients and healthcare professionals.

Hofstraat holds several positions in (inter)national advisory bodies. Amongst others, he is a member of the Dutch Sounding Board for Horizon 2020, contributing to work on Health, Demographic Change and Well-being. He is a member of the Steering Committee and co-initiator of the big data initiative of Top Sector Life Sciences & Health. He is also a member of the Management Team of the Institute for Diagnostic and Interventional Imaging (IDII), in which Philips participates together with UMC Utrecht, University Utrecht, and TU Eindhoven. He is a member of the Supervisory Board of the European Institute of Innovation & Technology (EIT) Health, and a member of the European Scientific Panel for Health.

Hans joined Philips Research from Akzo Nobel Central Research in 1998. He has also worked as a (part-time) Professor at the Institute of Molecular Chemistry of the University of Amsterdam, and at the Public Works Department of the Dutch Ministry of Transport and Public Works in The Hague. He graduated with a PhD in physical chemistry from the Free University Amsterdam (thesis awarded with the Royal Dutch Shell prize), and was a post-doc at the Eidgenössische Technische Hochschule, Zürich, Switzerland. He worked as a lecturer at the Free University, the Free University Medical Center, and the University College of Swaziland in Kwaluseni while completing his studies. Hans has authored about 200 publications with an h-index of 42 (Google Scholar) and holds 10 granted US patents.

https://www.linkedin.com/in/hofstraat/

Peter Ohnemus

President and CEO
Dacadoo, Switzerland

Peter Ohnemus is the founder of the dacadoo Health Score/dacadoo ag, Zurich/Switzerland. The patented dacadoo Health Score & Lifestyle Navigation Platform is being licensed to key Life & Health Insurance companies (Payers) and global healthcare operators (Providers). Peter has been involved in high-tech and bio-tech investments over the last 25 years and this had led to four IPO’s and multiple trade sells. Peter Ohnemus and his private investment firm Network Capital Holding are currently investing in high-tech and bio-tech start-ups. Peter was CEO & co-founded ASSET4 in 2004 with Goldman Sachs and Merrill Lynch as investors (the world’s leading provider of extra-financial information), which was sold to Thomson Reuters, New York in November 2009. Peter Ohnemus previously held senior executive positions with Sybase, Logic Works, The Fantastic Corporation and COS – all of which went public during his tenure. Peter Ohnemus was Entrepreneur of the Year (EoY) for Switzerland by EY. Peter is a frequent speaker and commenter on high-tech and healthcare globally. He has spoken at World Economic Forum (WEF), Fortune Brainstorm Health, Google Tech Talks, McKinsey’s Life Leaders CEO Forum, The Royal Society of Medicine, Stanford LIGHT Conference, CommunicAsia, Mobile World Congress, European Health Forum by the EU, Economist Global Healthcare Forum, Mobile Health Summit DC, European Tech Tour, Red Herring, WWW/Digital Disease Detection, etc. Over the last 10 years Peter has been board member of Rothschild Bank, Tele Denmark (Switzerland), Esbatech, CommerceOne, etc. Peter occasionally teaches digital innovation, entrepreneurship and economic impact at Universities such as HSG - Switzerland, Bocconi - India. Peter lives outside Zürich, is married and has 5 daughters.

Heidi Dohse

Sr. Program Manager, Healthcare & Life Sciences
Google Cloud, USA

In 1982 I was diagnosed with a rare arrhythmia and that was the beginning of my journey as a heart patient. I was one of the first AV ablations at University California San Francisco hospital in 1983 and have been 100% pacemaker dependent for over 30 years.

As a lifelong heart patient, I did not want to become a victim of heart disease. Instead I wanted to pursue my goal to become an athlete and competitive cyclist. After having open chest surgery in 2010, doing any kind of physical activity was a frightening idea. However, with the help of wearable devices and mobile apps, I had the data I needed to get from the hospital bed to across the finish line of my first bike race. Since then I have competed in cycling events both domestically and internationally. My mission is to inspire others to do amazing things!

Richard Daly

CEO
DNAnexus, Inc., USA

Richard has three decades of experience in building companies in healthcare and genomics, including 13 years at Baxter Laboratories. Subsequently to Baxter, Richard founded companies in both managed care and laboratory services and was also the CEO of Visible Genetics (NASDAQ: VGIN), the pioneer in laboratory-based gene sequencing and bioinformatics. Education includes a BS in finance from New York University and an MBA from Harvard University. 

Marvin Caruthers

Distinguished Professor, University of Colorado
& Co-founder, Amgen, Applied Biosystems, USA

Marvin H. Caruthers is a Distinguished Professor at the University of Colorado.  A Guggenheim Fellow, Dr. Caruthers completed the Ph.D. at Northwestern University and post-doctoral studies at MIT.

Professor Caruthers interests include nucleic acids chemistry and biochemistry. Approximately 35 years ago, the methodologies for chemically synthesizing DNA/RNA were developed in his laboratory and incorporated into instruments for synthesizing DNA/RNA as used by biochemists, biologists, and molecular biologists. More recently his laboratory has developed methods for RNA chemical synthesis and for the synthesis of DNA/RNA on chips. His laboratory has also pioneered the synthesis of many new nucleic acid analogs that have found applications in the nucleic acid diagnostic and therapeutic areas.

He is the recipient of several academic and research awards including The National Academy of Sciences Award in the Chemical Sciences, The Prelog Medal, The Economists Award in Biotechnology, and The US National Medal of Science. Dr. Caruthers is an elected member of The US National Academy of Sciences, The American Academy of Arts & Sciences, The National Inventors Hall of Fame, and a Corresponding Member of the German Academy of Science Gottingen. He is a co-founder of Amgen and Applied Biosystems.

Michael Baudis

Professor of Bioinformatics, Institute of Molecular Life Sciences (IMLS) and Swiss Institute of Bioinformatics (SIB), University of Zurich
Member of Global Alliance for Genomics and Health (GA4GH)

 

Michael Baudis is a Professor of Bioinformatics at the Institute of Molecular Life Sciences, University of Zurich, and a group leader at the Swiss Institute of Bioinformatics. Michael studied Medicine at Heidelberg University from which he graduated in 1998 and received his German medical license after internships at Heidelberg University Hospital. Between 1994 - 1998, he performed his research thesis in Molecular Cytogenetics in the group of Peter Lichter at the German Cancer Research Center (DKFZ) Heidelberg, on the genomic analysis of malignant lymphomas, in the context of a multi-center clinical trial. He received his doctorate of the Medical Faculty of the Ruprecht-Karls Universität Heidelberg in 1999. While working as an attending physician in Hematology & Oncology at Heidelberg University Hospital between 1998 and the end of 2000, Dr. Baudis pursued research projects in molecular cytogenetics and biology of hematologic neoplasias, and started to collect genomic profiling data from Comparative Genomic Hybridization (CGH) experiments. In January 2000, he began a postdoctoral research project at Stanford University, in the group of Prof. Michael Cleary (Department of Pathology) with focus on the functional characterisation of E2A-HLF and E2A-PBX1 fusion genes in acute lymphoblastic leukemias, using in vitro cell line models with inducible constructs and array based gene expression analysis as well as murine essays. This work was extended during the following faculty position at the University of Florida. Already during his thesis at the DKFZ, Michael became interested in the systematic collection of genome screening data, then from the CGH experiments performed at the Lichter lab. Supported by an internal grant from the University of Heidelberg's Medical School, he was able to create a database of original and publication derived genomic copy number data from malignant lymphomas. The website of the progenetix.net molecular cancer cytogenetics website was launched in early 2001, accompanied by a publication in Bioinformatics. Following a brief stay at the RWTH Aachen (Human Genetics; 2006-2007), since August 2007 Michael has been a group leader and Professor of Bionformatics (2015) at the Institute of Molecular Life Sciences of the University of Zürich, as well as associated with the Swiss Institute of Bioinformatics SIB. The work of his _Computational Oncogenomics_ group is centered on the comparative analysis of genomic profiling data in cancer, with a focus on somatic copy number variations (CNV, CNA). With the Progenetix and arrayMap repositories, the group provides some of the largest reference resources of curated genomic profiling and associated metadata covering the majority of cancer types. Apart from the analysis of cancer genome data, in recent years Michael has been involved in efforts to facilitate the access to genomic data for research on a global scale. Since its founding in 2014, Michael has been a member of the Global Alliance for Genomics and Health GA4GH, currently serving in the steering committee and as co-lead of its "Discovery" workstream. Related to the work in the Global Alliance, Michael also co-chairs the ELIXIR Beacon project, which develops APIs to query genomic data collections in a privacy-protecting manner. Here, the main focus on the group is in prototyping protocol extensions with demonstrator implementation in the Beacon+ project, connected to the Progenetix and arrayMap repositories. In the Swiss context, Michael has been involved in advising the Swiss Personalized Health Network (SPHN) initiative and currently leads its "Bioinformatics and Data Analytics" working group.

Tim Gibbons

Research Fellow
Clinical Informatics Research Unit, University of Southampton

Tim Gibbons has worked as a Research Fellow in the Clinical Informatics Research Unit at the University of Southampton since 2011. He has expertise in application design, NHS information governance and research system integrations.  Tim Gibbons will discuss a 20 year programme of work from the University of Southampton in the management and development of local and national research systems. Tim will present the programme’s evolution through technological, political and research landscape changes into its current multi-national collaborative application. 

Sven Nahnsen

Centre Head, Quantitative Biology Center Tübingen, Germany

Dr. Nahnsen studied Biomathematics and Biotechnolgy at the Universities Greifswald (Germany), Strasbourg (France) and Cambridge (UK). He received his PhD in Computer Science from the University of Tübingen in 2010. For many years he has been working at the interface of computer science and the biomedical sciences. He developed software solutions, as well as mathematical approaches for the analysis of modern high-throughput data. In 2012, he accepted the position as the head of the newly established Quantitative Biology Center (QBiC) in Tübingen. Together with his team he developed automated solutions for data and project management for clinical studies as well as bioinformatics methods for the integration of multi-scale omics data.

Michael Schroeder

Professor in Bioinformatics, Director of the Biotechnological center
Technical University Dresden, Germany

Michael Schroeder is a professor in bioinformatics and director of the biotechnological center of the Technical University Dresden. He has published some 200 papers and led numerous international research projects. He obtained his PhD in Computing from University of Hanover. From 2005 to 2015 he was CSO of Transinsight GmbH.

Brian O’Connor

Chair, European Connected Health Alliance, UK

Brian O’Connor was born in Belfast, Northern Ireland and has developed his career as a consultant, manager and/or investor in both private and public companies.

Brian has worked in the UK, the US and lived in Hong Kong for eleven years. He has gained vast experience as a company director in a variety of industries and professions, and has raised significant sums for companies through both private equity structures and stock exchange listings.

Through his long established consultancy company, Corporate Direction Ltd, he is currently providing strategic advice to Governments, International organisations and companies on the challenges facing healthcare in general and specifically on the Connected Health opportunity.

Healthcare experience

Brian has founded a number of companies in the healthcare services area in the UK, Ireland and Hong Kong.  He therefore has experience of the public and private health care systems in a number of countries and also an understanding of the often difficult balance between delivering care and making profit. He believes that overcoming the cultural and other barriers within healthcare is an interesting if sometimes frustrating challenge, but worthwhile if it leads to better patient care.

Brian is Chair of the European Connected Health Alliance organisation www.echalliance.com the rapidly expanding not for profit membership organisation.

It has created an International Network of Permanent Connected Health Ecosystems throughout Europe, to provide sustainable and structured opportunities for industry, academia and health and care providers and payers to meet and provide solutions to specific problems.

Charlotta Norgaard

Founder & CEO, Patient In Focus
Chairwoman, EUPATI

Charlotta Nørgaard started her healthcare career as a manager at the biotech giant, Genentech, in San Francisco, California in 2003. She directed the renowned Access Solutions department and led 6 drug launches. Later, she became the head of several consultancies incl. WG Consulting, a division of Gray Healthcare (a WPP company) with a focus on patient access, coverage and reimbursement, market access and HEOR.

Personal struggle with chronic diseases (including Systemic Lupus Erythematosus, arthritis, eczema and Hashimoto) led to Charlotta creating Lupus Friends and Family Foundation, a global non-profit patient organization that helps thousands of patients.

Charlotta is a public speaker, a clinical trial participant, a Wego Health Awards nominee (2016-2018) and a true co-creator in drug development. Her knowledge is sought after and her reach to other patients exceptional.

As a Patient Expert, Charlotta is recruited by public and private organizations in the US and Europe incl. hospitals, research centers, pharma, patient organizations, CROs, and even the National Institutes of Health (NIH) to ensure the patient voice is heard.

She has been actively involved in all areas of advocacy and activism to secure government funding for research, change state law to benefit the chronic ill, and to make a difference in patients’ lives. It is this passion that led her to found Patient Protocol, a mHealth company, that was instrumental in her own disease pathway. The company became successful in revolutionizing the clinical trial process by using a patient reported outcomes (PRO) program during washouts to achieve excellent trial results.

Charlotta has been featured in several publications incl. Journal of American Medical Association (JAMA) and is soon to be published for her research involvement as well.

She is the Chair of EUPATI Denmark, a EU Commission supported patient organization focusing on bringing clinical research and development education to patients to increase patient engagements. And she will be a EUPATI Fellow as of September 2018.

Isabelle Hilali

Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute

Isabelle Hilali is CRI - Center for Research & Interdisciplinarity’s Managing Director. CRI is a unique place that experiments and spreads new ways of learning, teaching, conducting research and mobilizing collective intelligence in life, learning and digital sciences. She is also Board Member of the Healthcare Data Institute, a think tank, that gathers
a large community of big data and health experts. As a true and positive leader, she is a dedicated professional committed to the health and education fields. Before joining CRI, Isabelle held several senior management positions in the eHealth field as well as in the mobile and internet industry, both in France and internationally. She holds a Masters
degree from “Institut d’Etudes Politiques (Sciences Po) de Grenoble” and “Université Paris I - Panthéon Sorbonne” in Military Strategy.

Helen Rostill

Director of Innovation, Development and Therapies
Surrey and Borders Partnership NHS Foundation Trust , UK

Professor Helen Rostill is a Consultant Clinical Psychologist and Board Director at Surrey and Borders Partnership NHS Foundation Trust with responsibility for strategy, new business, research and development, innovation, information technology strategy and therapies.  She is the Trust’s Chief Technology Officer.  Helen currently leads mental health programmes in Surrey Heartlands and Frimley Integrated Care Systems.  She is the Senior Responsible Officer for the TIHM (Technology Integrated Health Management) for dementia NHS Test Bed sponsored by the Department of Health, NHS England Office for Life Sciences.  She worked 10 years as a Senior Lecturer at the University of Birmingham and has published a wide range of research in national and international peer reviewed journals.  Her qualifications include a Doctorate in Clinical Psychology (Clin PsyD), a Postgraduate Diploma in Strategic Management and Leadership and a BSc (First Class Hons) in Psychology.  Helen is visiting Professor at the faculty of Health and Medical Sciences at the University of Surrey.

Michael Dahlweid

Chief Technology & Innovation Officer
Inselspital, University Hospital Bern, Switzerland

Fried-Michael Dahlweid is the director of technology and innovation of the Insel-Group, the largest Swiss healthcare delivery organization, including the university hospital of Bern. He is a board-certified emergency and trauma care physician, and graduated in both, medical informatics as well as in strategy, design thinking, and business administration. Before joining the university hospital Bern, he served as global chief medical officer for GE Healthcare and DXC Healthcare, respectively. Previously he ran different health IT software businesses operationally, including health software production at AGFA Healthcare, and served at the helm of large hospital groups’ IT businesses. He started and operated health tech start-ups and holds different board seats in the venture and health tech industry. Additionally, he has taken on advisory roles for international Governments, and acts as a lecturer at various universities. 

Neil Gomes

Executive Vice President and Chief Digital Officer
Jefferson Health, USA

Neil Gomes (B.Sc., MBA/MMS, M.Ed) is the Senior Vice President for Technology Innovation and Consumer Experience and Chief Digital Officer at Thomas Jefferson University and Jefferson Health System. Neil has worked for the Fortune 500 Tata Group of Companies where he played a leadership role in building the intrapreneurial startup, Tata Interactive Systems, from 60 employees to the world’s largest custom e-learning development firm with 650 employees in less than two years. Neil left the Tata Group to complete his M.Ed. in Instructional Design at the University of South Florida (USF) whilst progressively working towards the position of Director of eTeaching and Technology and then the Director of Instructional Design and Training at USF Health. While at USF, Neil’s leadership and entrepreneurial acumen helped grow a strategic team of application developers, instructional and multimedia designers, and project managers that generated over $1.5 million in annual auxiliary revenue from research and external development projects while growing online student enrollment from approx. 200 enrollments in 2002 to 60,000 enrollments a semester by 2012. While at USF, Neil also began working toward his Ph.D., is currently a Ph.D. Candidate (ABD), has authored research articles, a book chapter, and delivered several formal research presentations. At Jefferson, Neil drives digital innovation in healthcare, consumer experience and engagement, training, and education via teams of application and web/mobile developers, portal solutions developers, simulation and UI/UX designers, trainers, documentation and digital consumer experience specialists,instructional designers, e-learning developers, and IT support specialists. Neil also helps define innovation strategy and design innovation development programs via Jefferson’s Innovation Team. Recently, he helped secure a $15 million donor grant from the Bernie Marcus Foundation to develop a high-tech, consumer-centric, integrative health center at Jefferson and also launched a pioneering collaboration with the IBM Watson IoT team on developing “cognitive concierges” for hospitals.
Neil serves as Associate Editor of the Journal for Healthcare Transformation and is a contributor toward the book: We CAN fix Healthcare, the Future is NOW. Neil is also a speaker, agile aficionado, and digital innovation evangelist.

Payam Barnaghi

Professor of Machine Intelligence
University of Surrey, UK

Payam Barnaghi is Professor of Machine Intelligence at the University of Surrey. He is also technical lead for the TIHM for Dementia project, sponsored by NHS England and the Department of Health, and was coordinator and Principal Investigator of the EU FP7 CityPulse project on smart cities and large-scale data analytics. He is an associate editor of the IEEE Transactions on Big Data. He works on machine learning, Internet of Things (IoT), semantic web, service computing, adaptive algorithms, big data and information search and retrieval to solve problems and develop new technologies for the future Internet/Web and healthcare systems. 

Akos Tarcsay

Senior Application Scientist
Chemaxon, Hungary

Akos Tarcsay has nearly 10-year experience in computational chemistry and cheminformatics.  He spent 6 years as drug designer at Gedeon Richter Plc. and 4 years in cheminformatics field as Senior Application Scientist at ChemAoxn. His current responsibility is suggesting solutions to research informatics challenges relying on the ChemAxon portfolio. Msc in chemical engineering and biochemical engineering, PhD on the field of computational chemistry from Budapest University of Technology and Economics. Author or co-author of >15 publications.

Mark Steedman

Research Manager
Deloitte UK Centre for Health Solutions

Mark is a Research Manager in the Deloitte UK Centre for Health Solutions. He supports Deloitte’s Life Sciences and Health Care practices in identifying emerging trends, challenges, opportunities and examples of good practice, based on primary and secondary research and rigorous analysis. Until November 2016, he was the Institute Manager and a Policy Fellow at the Institute of Global Health Innovation at Imperial College London, where he supported research on palliative and end-of-life care, maternal and child health, design, philanthropy and electronic health records. Mark has a PhD from the UC Berkeley - UCSF Graduate Programme in Bioengineering, and he completed a Whitaker International Postdoctoral Fellowship in the Departments of Materials and Bioengineering at Imperial College London.

Related Videos

Presentation

Measuring the return from pharmaceutical innovation 2018

Related topics: Discovery & R&D Innovation, Digital & Technology
Availability: FREE

The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.

Speaker

Mark Steedman
Research Manager
Deloitte UK Centre for Health Solutions

Presentation

Extreme-Scale Cloud-Based Infrastructure needed for global genomic data

Related topics: IT & Big Data
Availability: FREE
  • Cloud genomic data sets are approaching a total of 250 Petabytes representing an unprecedented resource for research and clinical applications
  • Extreme-scale cloud-based compute and tools are required to federate and utilize the emerging global resource, conforming to localized compliance requirements
  • A rapid evolution in data resource architecture and applicable tools is required, with an important role to be played by Artificial Intelligence
Speaker

Richard Daly
CEO
DNAnexus, Inc., USA

Pricing & Registration

3 Day Delegate Pass
period. prices until 21.07.2019!
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
2,092 EUR
After 25% discount
2 Delegates
1,813 EUR
After 35% discount
3 Delegates
1,534 EUR
After 45% discount
4+ Delegates
1,395 EUR
After 50% discount
Solution Provider/Consultant
1 Delegate
2,790 EUR
2 Delegates
2,511 EUR
After 10% discount
3 Delegates
2,371 EUR
After 15% discount
4+ Delegates
2,232 EUR
After 20% discount
Government, Academic & Non-Profit
1 Delegate
499 EUR
2 Delegates
499 EUR
3 Delegates
499 EUR
4+ Delegates
499 EUR
Academic
1 Delegate
1,150 EUR
2 Delegates
1,150 EUR
3 Delegates
1,150 EUR
4+ Delegates
1,150 EUR
2 Day Delegate Pass
period. prices until 21.07.2019!
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
1,717 EUR
After 25% discount
2 Delegates
1,488 EUR
After 35% discount
3 Delegates
1,259 EUR
After 45% discount
4+ Delegates
1,145 EUR
After 50% discount
Solution Provider/Consultant
1 Delegate
2,290 EUR
2 Delegates
2,061 EUR
After 10% discount
3 Delegates
1,946 EUR
After 15% discount
4+ Delegates
1,832 EUR
After 20% discount
Academic
1 Delegate
950 EUR
2 Delegates
950 EUR
3 Delegates
950 EUR
4+ Delegates
950 EUR
Government, Academic & Non-Profit
1 Delegate
499 EUR
2 Delegates
499 EUR
3 Delegates
499 EUR
4+ Delegates
499 EUR

Upgrade your Attendance to become a Member!

(Only available for corporate registrations)

Upgrade to Silver Member (Add €199 to your current registration) and receive:
  • Video Library Access - Receive a 12 month video library subscription (Access to over 1000 Expert Presentations from our portfolio of events, searchable & viewable on demand with 300 more added annually!
  • Be recognized at our events for your loyalty.
  • Normally valued at €999
Upgrade to Gold Member (Add €999 to your current registration) and receive:
  • Free Event Pass - Attend an additional (one) NextLevel Event (in the 12 month period from your event’s dates). Just inform your NextLevel representative which event!
  • Video Library Access - Receive a 12 month video library subscription (Access to over 1000 Expert Presentations from our portfolio of events, searchable & viewable on demand with 300+ videos added annually!
  • Be recognized at our events for your loyalty.
  • Normally valued at over €3780

For more information click here to learn more: https://www.nextlevells.com/membership